Biogen Inc. (BIIB) stock
BIIBNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 28, 2026Score 4/3056% above fair value
$251.41+0.62 (+0.25%)
Close on Nov 18, 2026Market cap $37.16BP/E 107.4Yield –
Biogen pe ratio
The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.
Biogen's pe ratio was 44.9× on Nov 11, 2026, against 16.6× a year earlier. Over the last 5 years it ranged from 10.8× to 44.9×, with a median of 20.2×.
PE Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 44.9× | +28.8 |
| 2025 | Dec 31, 2025 | 16.0× | +2.2 |
| 2024 | Dec 31, 2024 | 13.8× | −11.9 |
| 2023 | Dec 29, 2023 | 25.7× | +11.6 |
| 2022 | Dec 30, 2022 | 14.1× | −9.4 |
| 2021 | Dec 31, 2021 | 23.5× | +15.4 |
| 2020 | Dec 31, 2020 | 8.1× | −2.4 |
| 2019 | Dec 31, 2019 | 10.6× | −8.9 |
| 2018 | Dec 31, 2018 | 19.5× | −0.1 |
| 2017 | Dec 29, 2017 | 19.5× | +3.5 |
| 2016 | Dec 30, 2016 | 16.0× | −4.0 |
| 2015 | Dec 31, 2015 | 20.0× | −12.1 |
| 2014 | Dec 31, 2014 | 32.1× | −7.1 |
| 2013 | Dec 31, 2013 | 39.2× | +10.2 |
| 2012 | Dec 31, 2012 | 29.0× | +1.1 |
| 2011 | Dec 30, 2011 | 27.9× | +7.6 |
| 2010 | Dec 31, 2010 | 20.3× | +2.4 |
| 2009 | Dec 31, 2009 | 18.0× | – |
See a number that looks wrong?